Navigation Links
FDA Approves New Once-a-Day HIV Pill
Date:8/27/2012

MONDAY, Aug. 27 (HealthDay News) -- A new pill to treat HIV infection that combines four medicines and only has to be taken once a day was approved by the U.S. Food and Drug Administration on Monday.

Stribild, which will be marketed by maker Gilead Sciences, contains the HIV drugs elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate. It will be prescribed to people who have never been treated for HIV infection, the agency said in a statement.

Two of the drugs, elvitegravir and cobicistat, are new, the FDA noted. Elvitegravir interferes with one of the enzymes that HIV needs to multiply, while cobicistat inhibits an enzyme that metabolizes certain HIV drugs and so prolongs the effect of elvitegravir. The combination of emtricitabine and tenofovir disoproxil fumarate is already marketed as Truvada, and they work in concert to block another enzyme that HIV needs to replicate.

"Through continued research and drug development, treatment for those infected with HIV has evolved from multi-pill regimens to single-pill regimens," Dr. Edward Cox, director of the Office of Antimicrobial Products in FDA's Center for Drug Evaluation and Research, said in the agency statement. "New combination HIV drugs like Stribild help simplify treatment regimens."

Earlier this year, the agency approved the first over-the-counter rapid HIV test for home use and gave its blessing to the first drug to be used to prevent HIV infection when used together with safe sex practices.

Two clinical trials found between 88 percent and 90 percent of patients treated with Stribild had an undetectable amount of HIV in their blood after 48 weeks of treatment, the FDA said.

The drug will carry a boxed warning that says it can cause a build-up of lactic acid in the blood and severe liver problems, both of which can be fatal. In the clinical trials, common side effects included nausea and diarrhea. Serious side effects include new or worsening kidney problems, decreased bone mineral density, fat redistribution and changes in the immune system, the FDA said.

Gilead, which is based in Foster City, Calif., must conduct more research to further determine the drug's safety in women and children, how resistance develops to Stribild and possible interactions with other drugs, the FDA said.

More information

For more on HIV drug therapies, visit the U.S. National Library of Medicine.

-- HealthDay staff

SOURCE: Aug. 27, 2012, news release, U.S. Food and Drug Administration


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. FDA Approves Generic Versions of Plavix
2. FDA Approves Combo Shot for Meningitis, Hib in Kids
3. FDA Approves SonixGPS Needle Guidance Technology for Vascular Access Procedures
4. FDA Approves First New Weight-Loss Drug in More Than a Decade
5. FDA Approves 1st Pill to Help Prevent HIV Infection
6. FDA Approves 2nd New Weight-Loss Drug
7. FDA Approves Flu Vaccine for Coming Season
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... The World Molecular Imaging Society ... Imaging.” The focus of ADDMI-IG will be geared towards how using molecular imaging ... Through ADDMI-IG WMIS will provide a platform for productive discussions about the implementation ...
(Date:5/25/2016)... ... May 25, 2016 , ... TransactRx announces the ... adjudication of medical service claims by Pharmacy Benefit Managers that were submitted by ... software. The TransactRx Cross Benefit Clearinghouse receives standard professional medical claims submitted from ...
(Date:5/25/2016)... ... 2016 , ... For more than fifty years, we've suffered whiplash as each new scientific study ... to the latest nutritional advice – advice that was supposed to keep us healthy and ... 3 American adults are considered to be overweight and more than 1 in 3 adults ...
(Date:5/25/2016)... ... , ... Consumer access to organic foods and grower access to food processers ... grain cereals and other plant-based foods, will introduce the first consumer product (a new ... by Hesco/Dakota Organic Products. , The transitional designation means the cereal was made using ...
(Date:5/24/2016)... ... , ... According to an article published May 11th on Fox ... the amount of calories they consumed by 25% experienced some interesting health benefits. This ... improved quality of life, and enhanced sexual function compared to the other group, which ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... 2016 Transparency Market Research has ... Insufficiency Market - Global Industry Analysis, Size, Share, Growth, ... the report, the exocrine pancreatic insufficiency market is anticipated ... to 2023 to reach US$2.85 Bn by 2023. ... by the deficiency of the exocrine pancreatic enzymes, causing ...
(Date:5/23/2016)... , May 23, 2016 ... Devices, Diagnostics and Monitoring, and Vision Care ... Which areas are going to grow at the fastest ... revenues to 2026, assessing data, trends, opportunities and prospects. ... charts, and graphs. Discover the most lucrative areas in ...
(Date:5/23/2016)... 2016 Non-invasive diagnostic test realizes ... diseases; ,Technology to be presented at Yissum’s booth, at ... Development Company of the Hebrew University of Jerusalem ... with Aurum Ventures MKI, the technology investment arm of ... diagnostic approach for early detection of multiple diseases by ...
Breaking Medicine Technology: